Clinical Trial Update: 99mTc-MIBI SPECT/CT in Breast Malignancy [NA]

View source ↗

Summary

The clinical trial evaluating 99mTc-MIBI SPECT/CT in breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 99mTc-MIBI (Technetium-99m sestamibi)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Breast Cancer | NA | Status: TERMINATED